Fig. 4: Cav-1 delivered by exosomes promotes CSC phenotypes.
From: The paracrine induction of prostate cancer progression by caveolin-1
Characterization of exosomes purified from LNCaP (Vc or Cav1OE) or Du145 (Vc, shCav1) based on a particle size, b particle number per cell, and c exosome markers (Alix, CD9, CD63, HSP70, HSP90). d The amount of Cav-1 in purified exosomes was determined by dot blot assay. Cav-1 concentration was analyzed by rCav-1 (0–100 ng) standard curve. e Prostate sphere formation of WT LNCaP was determined after treating with purified exosomes from LNCaP (Vc or Cav1OE) or Du145 (Vc, shCav1) for 14 days of treatment. Scale bar = 100 μm. Data were shown as mean ± SD (n > 10), n.s., non-significant, *P < 0.5, **P < 0.01, ***P < 0.001. f Du145 shCav1 cells were subcutaneously injected in immune-deficient mice then treated with PBS or TDEs purified from Du145 Vc (Exo-Vc) or Du145 shCav1 (Exo-shCav1), twice-a-week and tumor incidence was recorded at Week 5 and Week 7 post injection. And all tumors were collected at Week 7
